Recently, cetuximab, a mouse-human (IgG1) chimeric antibody against epidermal growth factor receptor (EGFR), was approved for treating head and neck cancer (HNC) including oral cancer. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.